Rho Capital Partners’s Tvardi Therapeutics TVRD Stock Holding History

Rho Capital Partners’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-41,641	Closed	-$20.9M	–	7
2021 Q2	$21.4M	Sell	41,641 -29,166	-41%	-$18.5M	1.96%	4
2021 Q1	$55.3M	Sell	70,807 -6,945	-9%	-$4.75M	5.32%	4
2020 Q4	$42.4M	Hold	77,752	–	–	22.29%	2
2020 Q3	$35.6M	Hold	77,752	–	–	29.66%	2
2020 Q2	$47.9M	Sell	77,752 -10,944	-12%	-$6.04M	31%	2
2020 Q1	$42.2M	Hold	88,696	–	–	42.5%	2
2019 Q4	$51.4M	Hold	88,696	–	–	39.1%	2
2019 Q3	$58.4M	Sell	88,696 -2,083	-2%	-$1.73M	48.88%	1
2019 Q2	$70.3M	Sell	90,779 -8,334	-8%	-$5.86M	48.74%	1
2019 Q1	$70M	Hold	99,113	–	–	74.08%	1
2018 Q4	$46.4M	Hold	99,113	–	–	68.07%	1
2018 Q3	$85.5M	Hold	99,113	–	–	78.61%	1
2018 Q2	$68.3M	Hold	99,113	–	–	65.36%	1
2018 Q1	$44.2M	Hold	99,113	–	–	62.3%	1
2017 Q4	$43.7M	Hold	99,113	–	–	75.9%	1
2017 Q3	$48.8M	Hold	99,113	–	–	76.92%	1
2017 Q2	$54.9M	Hold	99,113	–	–	76.67%	1
2017 Q1	$65.6M	Buy	99,113 +13,889	+16%	+$7.42M	92.21%	1
2016 Q4	$28.5M	Hold	85,224	–	–	21.84%	2
2016 Q3	$25.6M	Hold	85,224	–	–	17.3%	3
2016 Q2	$14.8M	Hold	85,224	–	–	11.8%	4
2016 Q1	$19.1M	Buy	85,224 +11,111	+15%	+$3.32M	10.45%	5
2015 Q4	$45M	Hold	74,113	–	–	15.47%	3
2015 Q3	$38.1M	Hold	74,113	–	–	12.66%	3
2015 Q2	$32.4M	Hold	74,113	–	–	11.33%	4
2015 Q1	$26.8M	Hold	74,113	–	–	11.18%	4
2014 Q4	$26.6M	Hold	74,113	–	–	11.8%	4
2014 Q3	$22.4M	Hold	74,113	–	–	11.24%	4
2014 Q2	$45.4M	Hold	74,113	–	–	17.64%	3
2014 Q1	$49.7M	Buy	+74,113	New	+$43.8M	19.38%	3

Other funds holding TVRD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Rho Capital Partners's TVRD Position: Q3 2021 in Review

Rho Capital Partners sold out of Tvardi Therapeutics (TVRD) in Q3 2021, closing a stake of 41,641 shares — an estimated $20.9M sold.

Rho Capital Partners first reported a position in TVRD in Q1 2014 and held it in 30 quarters. The position peaked at $85.5M in Q3 2018. 169 funds tracked by Wall St. Rank hold TVRD as of Q3 2021.

Rho Capital Partners reported no remaining Tvardi Therapeutics position as of Q3 2021 after selling out during the quarter.
Rho Capital Partners sold 41,641 Tvardi Therapeutics shares in Q3 2021, an estimated $20.9M.
Rho Capital Partners first reported a position in Tvardi Therapeutics in Q1 2014 and held it in 30 quarters.
Rho Capital Partners's Tvardi Therapeutics position peaked at $85.5M in Q3 2018.
169 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2021.

Based on Rho Capital Partners's 13F filing for Q3 2021, filed 12 Nov 2021.